361 filings
DEFA14A
NRXP
NRX Pharmaceuticals Inc
18 Mar 24
Additional proxy soliciting materials
4:00pm
DEFA14A
NRXP
NRX Pharmaceuticals Inc
13 Mar 24
Additional proxy soliciting materials
5:08pm
DEF 14A
NRXP
NRX Pharmaceuticals Inc
Definitive proxy
11 Mar 24
5:16pm
8-K
NRXP
NRX Pharmaceuticals Inc
6 Mar 24
Other Events
4:08pm
8-K
NRXP
NRX Pharmaceuticals Inc
28 Feb 24
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
5:09pm
424B5
9fyc hktnrw
28 Feb 24
Prospectus supplement for primary offering
10:40am
424B5
n8hufalkckr
26 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
idve9tm95j
14 Feb 24
Entry into a Material Definitive Agreement
4:30pm
8-K
hf3brev7nlm40mitdifm
14 Feb 24
Entry into a Material Definitive Agreement
6:03am
8-K
bzin 9ahvn
2 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:37pm
8-K
v69n7evr4t1j
23 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:16pm
3
e1nqnjc mrx9gb
16 Jan 24
NRX Pharmaceuticals / Janet Rehnquist ownership change
6:36pm
8-K
6dvqv6t2cbfj kyq7xgq
29 Dec 23
Departure of Directors or Certain Officers
4:15pm
8-K
h6nobmgj19
21 Dec 23
Other Events
4:05pm
ARS
4re z8pdy8t16dbz6
22 Nov 23
Annual report to shareholders
4:32pm
8-K/A
rvg5qns
22 Nov 23
Changes in Registrant's Certifying Accountant
4:30pm
8-K
gdcp2qr9wdlhqwe54gm
21 Nov 23
Changes in Registrant's Certifying Accountant
5:23pm
8-K
muv9w kxh
14 Nov 23
NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
12:00am